PT Murni Sadar Tbk (MTMH.JK)
IDR 980.0
(-2.49%)
IDR 980.0
(-2.49%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 155.6 Billion IDR | -9.6% |
| 2022 | 227.09 Billion IDR | -51.56% |
| 2021 | 300.93 Billion IDR | 332.67% |
| 2020 | 114.3 Billion IDR | 563.13% |
| 2019 | -16.53 Billion IDR | -171.89% |
| 2018 | 22.99 Billion IDR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 36.61 Billion IDR | -25.79% |
| 2024 Q2 | 43.79 Billion IDR | -10.74% |
| 2024 Q1 | 51.03 Billion IDR | 50.68% |
| 2023 Q2 | 4.5 Billion IDR | -83.25% |
| 2023 Q3 | 34.55 Billion IDR | 666.48% |
| 2023 Q4 | 34.84 Billion IDR | 0.84% |
| 2023 Q1 | 26.91 Billion IDR | -45.09% |
| 2023 FY | - IDR | -9.6% |
| 2022 FY | - IDR | -51.56% |
| 2022 Q4 | 49.01 Billion IDR | 110.89% |
| 2022 Q2 | 26.59 Billion IDR | -56.81% |
| 2022 Q1 | 61.57 Billion IDR | 236.78% |
| 2022 Q3 | 23.24 Billion IDR | -12.62% |
| 2021 Q1 | 124.13 Billion IDR | 0.0% |
| 2021 Q3 | 72.22 Billion IDR | -41.81% |
| 2021 Q2 | 124.13 Billion IDR | 0.0% |
| 2021 FY | - IDR | 332.67% |
| 2021 Q4 | -45.01 Billion IDR | -162.33% |
| 2020 FY | - IDR | 563.13% |
| 2019 FY | - IDR | -171.89% |
| 2018 FY | - IDR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| PT Bundamedik Tbk | 223.9 Billion IDR | 30.504% |
| PT Metro Healthcare Indonesia Tbk | -7.68 Billion IDR | 2126.08% |
| PT Medikaloka Hermina Tbk | 1584.42 Billion IDR | 90.179% |
| PT Mitra Keluarga Karyasehat Tbk | 1555.38 Billion IDR | 89.996% |
| PT Famon Awal Bros Sedaya Tbk | 443.01 Billion IDR | 64.875% |
| PT Royal Prima Tbk | 52.4 Billion IDR | -196.915% |
| PT Kedoya Adyaraya Tbk | 61.12 Billion IDR | -154.585% |
| PT Sarana Meditama Metropolitan Tbk | 323.18 Billion IDR | 51.852% |
| PT Siloam International Hospitals Tbk | 2692.46 Billion IDR | 94.221% |
| PT Sejahteraraya Anugrahjaya Tbk | 437.22 Billion IDR | 64.411% |